Skip to main content

Table 3 Baseline characteristics of the participants

From: Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients—rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial

Total number

976

Age (years)

63.5 ± 10.0

Sex, men (%)

60.5

Underlying renal disease, diabetic nephropathy (%)

42.5

Years on hemodialysis, 5 years or longer (%)

52.2

Prior cardiovascular disease, present (%)

25.1

Serum calcium (mg/dL)

8.82 ± 0.60

Serum phosphate (mg/dL)

4.56 ± 0.91

Serum intact parathyroid hormone (pg/mL)

86.6 (46.8–130.0)

Use of calcium carbonate (%)

82.9

Use of sevelamer hydrochloride (%)

32.0

Use of lanthanum carbonate (%)

12.4

Use of cinacalcet hydrochloride (%)

5.9

  1. The table gives number, percentage, mean ± standard deviation, or median (25th–75th percentile)